OncoAlert

An Amazing Day 3 of #ESTRO26 KUDOS to Our friends at ESTRO for such an amazing meeting and looking forward to all that is to come in the following days. Amazing Stats coming from X ✅️ 14 million impressions (in 2025 Total ESTRO impressions 7,2 million) ✅️ 730 posts And so much more to come!! OncoAlert is Beyond proud to be an ESTRO partner!! WE ARE ALL OncoAlert 🚨 #RadOnc @ESTRO_RT @DrewMoghanaki @LindaMrissa @christian_roenn @Valeriadionisi @jaydetsky @piet_ost @jryckman3 @B_Tomasik @gmpetrianni @CiroFranzese1 @Xristodouleas @piet_ost @radoncreview @BlanceS90 @DrSpratticus @BarbaraJereczek @Mat_Guc @ZilliThomas @_ShankarSiva @PBlanchardMD @achoud72 @MKnoll_MD @jryckman3 @Icro_Meattini @seanmmcbride @DavidSherMD @to_be_elizabeth @AmadeoWals @LuisAlberto3P @brachyexpert @DrLesterColl

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial Presented by Isabel Syndikus 🇬🇧 #RadOnc ☢️ In the PIVOTALboost trial, we treated 1314 men with high-risk localised prostate cancer with hormone therapy and radiotherapy to the prostate ± boost ± pelvic nodes (60/67/47Gy, 20 fractions). Adding a focal boost did not increase early side effects. Pelvic node radiotherapy increased early bowel side effects. Early data at 2 years suggest low levels of late toxicity with no difference between the arms. Moderately hypo-fractionated boost radiotherapy is safe. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Cuidado: la #SBRT prostática en 2 fracciones muestra buena toxicidad a 2 años (HERMES), pero la toxicidad crónica tardía (>2-3 años) sigue siendo el gran interrogante. Necesitamos seguimiento largo y ensayos más grandes antes de adoptarla ampliamente. #ESTRO26

Great study presented by #TanVivian demonstrating the benefits of SBRT in all patients, regardless of their operability #ESTRO26

5-year results of FASTRACK II by @_ShankarSiva 🔥 🔥 #ESTRO26

❗️ The OLIGOMA trial results just dropped at #ESTRO26 and they are massive. A 15-month improvement in median PFS for OMD breast cancer (HR = 0.48). This adds to the growing mountain of evidence that MDT (Metastasis-Directed Therapy) works. Lets’s go 🧵 1/n

✅ HERMES muestra buena toxicidad a corto plazo con #SBRT prostática en solo 2 fracciones. 📷OTROS ENSAYOS (PACE-B y series) advierten de toxicidad urinaria crónica tardía (>2-3 años). Seguimiento largo esencial antes de adoptarlo de forma rutinaria. #Prostatecancer #ESTRO26

A GREAT DAY 3 of #ESTRO26 🇸🇪We proudly introduce Prof @NehaVapiwala 🇺🇸Who talks to us about How can @ASTRO_org and @ESTRO_RT strengthen collaboration to advance global standards in radiation oncology? #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Side effects of moderately hypofractionated prostate and pelvic lymph node IMRT; results from the phase 3 PIVOTALboost randomised trial Presented by Isabel Syndikus 🇬🇧 #RadOnc ☢️ In the PIVOTALboost trial, we treated 1046 men with high-risk localised prostate cancer with hormone therapy and radiotherapy to the prostate ± pelvic nodes (60Gy /47Gy, 20 fractions). Early bowel, but not bladder side effects were more common in those with pelvic node radiotherapy. Cumulative late bowel and bladder event rates up to 2 years were low and similar in both arms. Moderately hypo-fractionated pelvic node radiotherapy is safe. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Long-Term Survival and Toxicity Outcomes in Over 1,200 Men Aged ≤60 Years Treated with LDR Brachytherapy Presented by William Hayhurst 🇬🇧 #RadOnc ☢️ Low-dose-rate brachytherapy provides excellent long-term oncological control across all risk groups in younger men with prostate cancer, achieving >92%% cancer-specific survival and durable biochemical control at 20 years. Treatment is associated with a favourable toxicity profile and minimal long-term impact on urinary, bowel, and erectile function. Our findings support its use alongside surgery and stereotactic body radiotherapy as a definitive, effective treatment option for patients with longer life expectancy. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

@TonyFelefly @OncoAlert @safaviaa Here are some details! On OLIGOMA, nearly 3/4 were first line endocrine or chemotherapy. #ESTRO26 #OncTwitter @CJTsaiMDPhD

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer #ESTRO26 buff.ly/qIm2M6Q EORTC 22922/10925 randomized 4004 patients with stage I–III #BreastCancer to internal mammary/medial supraclavicular radiotherapy (IM-MS-RT) or no regional nodal irradiation☢️ After 22.2 years’ median follow-up, IM-MS-RT reduced breast cancer mortality (18.6% vs. 22.4%) but did not improve overall, disease-free, or distant metastases-free survival. Increased late non–breast cancer deaths and higher cardiac and pulmonary toxicities offset benefits, underscoring the need for prolonged follow-up in favorable-prognosis cancers treated with contemporary multimodality therapy. @KaidarOrit #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Salvage Hypofractionated Accelerated versus Standard Radiotherapy for Biochemical Recurrence after Radical Prostatectomy (SHARE): A Phase 3 Randomized Clinical Trial Presented by Youngju Song 🇰🇷 #RadOnc ☢️ The 4-year biochemical progression-free survival rates were similar (80.1% in the hypofractionated arm and 78.1% in the conventional arm). Although late gastrointestinal toxicities were more frequent in the hypofractionated arm, they were not severe and self-limiting. Considering that there was no significant difference in patient-reported outcomes, hypofractionated radiotherapy could be considered a viable alternative treatment option in the salvage setting. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Comparing Quality of Life (QOL) after adjuvant breast regional nodal radiotherapy (RNRT) within HYPORT Adjuvant trial (NCT03788213) Presented by SANJOY CHATTERJEE 🇮🇳 @AhmadAmeri9 #RadOnc ☢️ HYPORT Adjuvant study is India's first multicentre prospective randomised controlled trial testing ultrahypofractionated (5-fractions) versus standard moderately hypofractionated (15-fractions) radiotherapy, in adjuvant breast cancer setting. We report QOL comparisons in the regional nodal irradiation (RNI) cohort. Ultrahypofractionated RNI did not show any detrimental interactions on QOL compared to standard regime. Detailed QOL analysis including symptoms, functional, emotional, social and global QOL scores were similar between the arms. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Towards objective cosmetic self-evaluation: machine-learning on photographs from breast conserving treatment with validation on external trial dataset Presented by Morten Sahlertz 🇩🇰 #RadOnc ☢️ Objective assessment of cosmetic outcome after breast-conserving treatment is valuable to reduce subjectivity, enable consistent follow-up, and identify patients needing additional care. We developed machine-learning models using patient photographs in a large Danish cohort with external UK validation. Models combining image-derived features with clinical and patient-reported data outperformed image-only approaches and existing methods. These findings support scalable, image-based tools to complement patient-reported outcomes in routine follow-up. #BreastCancer @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward Trial Nodal Sub-study Presented by Saranya Ravindra 🇬🇧 #RadOnc ☢️ #BreastCancer Arm lymphoedema is a recognised complication of locoregional treatment for breast cancer. Using data from the FAST-Forward nodal sub-study, the aim of this analysis was to investigate the association between patient, tumour and treatment factors and development of long-term arm swelling. Axillary surgery was the main independent predictor of 5-year patient- and clinician-reported arm lymphoedema. This supports de-escalation of axillary surgery as the main means of reducing long-term arm lymphoedema. @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Great data today on prostate cancer @ESTRO_RT Isabel Syndikus presenting the adverse events of the PIVOTALboost trial prostate vs prostate and pelvis in 20 fractions- no long term differences in side effects @EmmaHall71

🎯 100% Local Control & 100% Cancer-Specific Survival. Long-term results of the FASTRACK II trial primary #kidneycancer. ✅ No local failures or cancer deaths ✅ Safe for high-risk/inoperable patients ✅ Kidney function preserved long-term #ESTRO26 #RadOnc #SABR @_ShankarSiva

📢Final EORTC 22922/10925 trial results presented at #ESTRO26 20‑year data shows lymph node RT lowers breast cancer mortality but not overall survival, highlighting the need for very long‑term follow‑up. 👉 eortc.org/blog/2026/05/1… #EORTCbreast #EORTCradiationoncology

Hypofractionated pelvic radiotherapy is safe & well tolerated. Prof Syndikus presentation of the PIVOTAL BOOST trial at #ESTRO26